Please use this identifier to cite or link to this item:
Title: Enhancing the Efficacy of Stem Cell Therapy with Glycosaminoglycans
Authors: Ling, L.
Ren, X. 
Cao, X. 
Hassan, A.B.M. 
Mah, S.
Sathiyanathan, P.
Smith, R.A.A.
Tan, C.L.L.
Eio, M.
Samsonraj, R.M.
van Wijnen, A.J.
Raghunath, M. 
Nurcombe, V.
Hui, J.H.
Cool, S.M. 
Keywords: cartilage repair
ex vivo expansion
heparan sulfate
osteochondral regeneration
Issue Date: 2020
Publisher: Cell Press
Citation: Ling, L., Ren, X., Cao, X., Hassan, A.B.M., Mah, S., Sathiyanathan, P., Smith, R.A.A., Tan, C.L.L., Eio, M., Samsonraj, R.M., van Wijnen, A.J., Raghunath, M., Nurcombe, V., Hui, J.H., Cool, S.M. (2020). Enhancing the Efficacy of Stem Cell Therapy with Glycosaminoglycans. Stem Cell Reports 14 (1) : 105-121. ScholarBank@NUS Repository.
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Abstract: Human mesenchymal stem cell (hMSC) therapy offers significant potential for osteochondral regeneration. Such applications require their ex vivo expansion in media frequently supplemented with fibroblast growth factor 2 (FGF2). Particular heparan sulfate (HS) fractions stabilize FGF2-FGF receptor complexes. We show that an FGF2-binding HS variant (HS8) accelerates the expansion of freshly isolated bone marrow hMSCs without compromising their naivety. Importantly, the repair of osteochondral defects in both rats and pigs is improved after treatment with HS8-supplemented hMSCs (MSCHS8), when assessed histologically, biomechanically, or by MRI. Thus, supplementing hMSC culture media with an HS variant that targets endogenously produced FGF2 allows the elimination of exogenous growth factors that may adversely affect their therapeutic potency. © 2019 The AuthorsThis study highlights a novel strategy to improve cartilage repair using hMSCs cultured with heparan sulfates that target and stabilize fibroblast growth factor 2. The work is focused on developing bio-additives that prevent the loss of hMSCs stemness during their ex vivo expansion that is important for maintaining their therapeutic utility. © 2019 The Authors
Source Title: Stem Cell Reports
ISSN: 2213-6711
DOI: 10.1016/j.stemcr.2019.12.003
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1016_j_stemcr_2019_12_003.pdf5.4 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons